WO2006009862A2 - Amebiasis subunit vaccine - Google Patents
Amebiasis subunit vaccine Download PDFInfo
- Publication number
- WO2006009862A2 WO2006009862A2 PCT/US2005/021507 US2005021507W WO2006009862A2 WO 2006009862 A2 WO2006009862 A2 WO 2006009862A2 US 2005021507 W US2005021507 W US 2005021507W WO 2006009862 A2 WO2006009862 A2 WO 2006009862A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vaccine
- subunit peptide
- residue
- peptide
- subunit
- Prior art date
Links
- 208000004881 Amebiasis Diseases 0.000 title description 16
- 206010001980 Amoebiasis Diseases 0.000 title description 16
- 229940031626 subunit vaccine Drugs 0.000 title description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 194
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 86
- 241000224432 Entamoeba histolytica Species 0.000 claims abstract description 82
- 239000002523 lectin Substances 0.000 claims abstract description 70
- 241000204733 Entamoeba dispar Species 0.000 claims abstract description 27
- 238000000034 method Methods 0.000 claims abstract description 23
- 229940007078 entamoeba histolytica Drugs 0.000 claims abstract description 20
- 241000288906 Primates Species 0.000 claims abstract description 16
- 230000016784 immunoglobulin production Effects 0.000 claims abstract description 9
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 8
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 8
- 239000002157 polynucleotide Substances 0.000 claims abstract description 8
- 229960005486 vaccine Drugs 0.000 claims description 67
- 150000001413 amino acids Chemical class 0.000 claims description 55
- 208000015181 infectious disease Diseases 0.000 claims description 49
- 108020004414 DNA Proteins 0.000 claims description 22
- 238000006467 substitution reaction Methods 0.000 claims description 18
- 229920001184 polypeptide Polymers 0.000 claims description 17
- 125000000539 amino acid group Chemical group 0.000 claims description 16
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
- 230000004048 modification Effects 0.000 claims description 5
- 238000012986 modification Methods 0.000 claims description 5
- 239000002773 nucleotide Substances 0.000 claims description 5
- 125000003729 nucleotide group Chemical group 0.000 claims description 5
- 150000004676 glycans Chemical class 0.000 claims description 4
- 238000010255 intramuscular injection Methods 0.000 claims description 4
- 239000007927 intramuscular injection Substances 0.000 claims description 4
- 231100000252 nontoxic Toxicity 0.000 claims description 4
- 230000003000 nontoxic effect Effects 0.000 claims description 4
- 229920001282 polysaccharide Polymers 0.000 claims description 4
- 239000005017 polysaccharide Substances 0.000 claims description 4
- 238000010254 subcutaneous injection Methods 0.000 claims description 4
- 239000007929 subcutaneous injection Substances 0.000 claims description 4
- 230000037406 food intake Effects 0.000 claims description 3
- 239000002269 analeptic agent Substances 0.000 claims description 2
- 239000000568 immunological adjuvant Substances 0.000 claims description 2
- 229940023041 peptide vaccine Drugs 0.000 abstract description 35
- 210000002966 serum Anatomy 0.000 description 69
- 239000012634 fragment Substances 0.000 description 64
- 208000006503 Amebic Liver Abscess Diseases 0.000 description 50
- 206010063741 Hepatic amoebiasis Diseases 0.000 description 50
- 235000001014 amino acid Nutrition 0.000 description 49
- 229940024606 amino acid Drugs 0.000 description 48
- 108090001090 Lectins Proteins 0.000 description 35
- 102000004856 Lectins Human genes 0.000 description 35
- 230000005875 antibody response Effects 0.000 description 29
- 108090000623 proteins and genes Proteins 0.000 description 29
- 230000000968 intestinal effect Effects 0.000 description 28
- 235000018102 proteins Nutrition 0.000 description 28
- 102000004169 proteins and genes Human genes 0.000 description 28
- 238000002965 ELISA Methods 0.000 description 23
- 239000002671 adjuvant Substances 0.000 description 23
- 239000000203 mixture Substances 0.000 description 23
- 102000009016 Cholera Toxin Human genes 0.000 description 22
- 108010049048 Cholera Toxin Proteins 0.000 description 22
- 125000003275 alpha amino acid group Chemical group 0.000 description 19
- 230000036039 immunity Effects 0.000 description 19
- 241001529936 Murinae Species 0.000 description 18
- 241000282520 Papio Species 0.000 description 17
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 17
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 17
- 108010039918 Polylysine Proteins 0.000 description 14
- 230000002550 fecal effect Effects 0.000 description 14
- 229920000656 polylysine Polymers 0.000 description 14
- 230000001681 protective effect Effects 0.000 description 14
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 13
- 206010022678 Intestinal infections Diseases 0.000 description 13
- 229940098773 bovine serum albumin Drugs 0.000 description 13
- 238000002255 vaccination Methods 0.000 description 12
- 210000003608 fece Anatomy 0.000 description 11
- 239000000427 antigen Substances 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 10
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 10
- 244000045947 parasite Species 0.000 description 10
- 229940023143 protein vaccine Drugs 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 241000282412 Homo Species 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 230000002163 immunogen Effects 0.000 description 8
- 238000013507 mapping Methods 0.000 description 8
- 230000002788 anti-peptide Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 210000004408 hybridoma Anatomy 0.000 description 7
- 230000003053 immunization Effects 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 7
- 108010038196 saccharide-binding proteins Proteins 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 210000003812 trophozoite Anatomy 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 6
- 230000000890 antigenic effect Effects 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 241000024188 Andala Species 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000011725 BALB/c mouse Methods 0.000 description 4
- 101710088138 Galactose-inhibitable lectin Proteins 0.000 description 4
- 102000015728 Mucins Human genes 0.000 description 4
- 108010063954 Mucins Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000000112 colonic effect Effects 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 229930182830 galactose Natural products 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 229920000136 polysorbate Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 208000031504 Asymptomatic Infections Diseases 0.000 description 3
- 101000881168 Homo sapiens SPARC Proteins 0.000 description 3
- 108091006905 Human Serum Albumin Proteins 0.000 description 3
- 102000008100 Human Serum Albumin Human genes 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 3
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 101000621511 Potato virus M (strain German) RNA silencing suppressor Proteins 0.000 description 3
- 102100037599 SPARC Human genes 0.000 description 3
- -1 aimethylglycine Chemical compound 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 206010009887 colitis Diseases 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 229910003460 diamond Inorganic materials 0.000 description 3
- 239000010432 diamond Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000001976 enzyme digestion Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229940051875 mucins Drugs 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000003071 parasitic effect Effects 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 241000224489 Amoeba Species 0.000 description 2
- 206010001985 Amoebic colitis Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 206010008631 Cholera Diseases 0.000 description 2
- 241000224431 Entamoeba Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000711408 Murine respirovirus Species 0.000 description 2
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 2
- 108020001027 Ribosomal DNA Proteins 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 108010008038 Synthetic Vaccines Proteins 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 229940124323 amoebicide Drugs 0.000 description 2
- 230000000398 anti-amebic effect Effects 0.000 description 2
- 239000000059 antiamebic agent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 108010074605 gamma-Globulins Proteins 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000003205 genotyping method Methods 0.000 description 2
- 238000011556 gerbil model Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 210000002850 nasal mucosa Anatomy 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 229940126583 recombinant protein vaccine Drugs 0.000 description 2
- 229940124551 recombinant vaccine Drugs 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229940125575 vaccine candidate Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- FJLUATLTXUNBOT-UHFFFAOYSA-N 1-Hexadecylamine Chemical compound CCCCCCCCCCCCCCCCN FJLUATLTXUNBOT-UHFFFAOYSA-N 0.000 description 1
- KJCVRFUGPWSIIH-UHFFFAOYSA-N 1-naphthol Chemical compound C1=CC=C2C(O)=CC=CC2=C1 KJCVRFUGPWSIIH-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- PYAFUXYGTYWWBP-UHFFFAOYSA-N 19-methoxynonadecane-1,2,3-triol Chemical compound COCCCCCCCCCCCCCCCCC(O)C(O)CO PYAFUXYGTYWWBP-UHFFFAOYSA-N 0.000 description 1
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108010000916 Fimbriae Proteins Proteins 0.000 description 1
- 108010046569 Galectins Proteins 0.000 description 1
- 102000007563 Galectins Human genes 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000005548 Hexokinase Human genes 0.000 description 1
- 108700040460 Hexokinases Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010024652 Liver abscess Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 102000005717 Myeloma Proteins Human genes 0.000 description 1
- 108010045503 Myeloma Proteins Proteins 0.000 description 1
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- UOZODPSAJZTQNH-UHFFFAOYSA-N Paromomycin II Natural products NC1C(O)C(O)C(CN)OC1OC1C(O)C(OC2C(C(N)CC(N)C2O)OC2C(C(O)C(O)C(CO)O2)N)OC1CO UOZODPSAJZTQNH-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102100029251 Phagocytosis-stimulating peptide Human genes 0.000 description 1
- 102000009569 Phosphoglucomutase Human genes 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 108700031314 Rotavirus VP6 Proteins 0.000 description 1
- 241000609103 Sarcophaga africa Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108010084754 Tuftsin Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 230000003816 axenic effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000012219 cassette mutagenesis Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- RNPXCFINMKSQPQ-UHFFFAOYSA-N dicetyl hydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(=O)OCCCCCCCCCCCCCCCC RNPXCFINMKSQPQ-UHFFFAOYSA-N 0.000 description 1
- 229940093541 dicetylphosphate Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229960003497 diloxanide furoate Drugs 0.000 description 1
- BDYYDXJSHYEDGB-UHFFFAOYSA-N diloxanide furoate Chemical compound C1=CC(N(C(=O)C(Cl)Cl)C)=CC=C1OC(=O)C1=CC=CO1 BDYYDXJSHYEDGB-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 244000000021 enteric pathogen Species 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229930186900 holotoxin Natural products 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000008073 immune recognition Effects 0.000 description 1
- 210000004201 immune sera Anatomy 0.000 description 1
- 229940042743 immune sera Drugs 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 230000017555 immunoglobulin mediated immune response Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000007193 modulation by symbiont of host erythrocyte aggregation Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000008881 mucosal defense Effects 0.000 description 1
- 230000016379 mucosal immune response Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- UOZODPSAJZTQNH-LSWIJEOBSA-N paromomycin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO UOZODPSAJZTQNH-LSWIJEOBSA-N 0.000 description 1
- 229960001914 paromomycin Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 108091000115 phosphomannomutase Proteins 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 210000004896 polypeptide structure Anatomy 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 229940035670 tuftsin Drugs 0.000 description 1
- IESDGNYHXIOKRW-LEOABGAYSA-N tuftsin Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](CCCNC(N)=N)C(O)=O IESDGNYHXIOKRW-LEOABGAYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000012762 unpaired Student’s t-test Methods 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 229940124931 vaccine adjuvant Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- AI35840 from NIAID.
- the government may have certain rights in the invention.
- Entamoeba histolytica are members of a large genus of naked rhizopod protozoans.
- E. histolytica is a parasitic amoeba of humans that can cause breakdown of body tissues during infection.
- E. histolytica is extremely common. Worldwide, in endemic areas such as India, Africa, Asia, Mexico, and South America, up to 20% of the population is infected each year. Of those with infections, only about 10% develop symptoms such as colitis or liver abscess. The low incidence of symptoms is thought to be due to a balance between host immune surveillance, parasite strain variation, and local factors such as diet or bacterial flora.
- the "pathogenic form" of amebic intestinal infection refers to E.
- Nonpathogenic form of amebiasis refers to Entamoeba dispar.
- E. dispar is morphologically identical to E. histolytica but is genetically a distinct species, which is harbored asymptomatically by carriers of the infection.
- Subjects who eventually exhibit symptoms harbor E. histolytica which was first established on the basis of their distinctive hexokinase and phosphoglucomutase isoenzymes, and later on the basis of antigen specificity in ELISA or by genetic differences by PCR. It is known that E.
- histolytica infection is mediated at least in part by the "Gal/GalNAc" adherence lectin.
- the purified lectin was shown to have a non- reduced molecular weight of 260 kDa on SDS-PAGE; reduction with ⁇ - mercaptoethanol yielded two subunits having molecular masses of 170 kDa (heavy subunit) and 35 kDa (light subunit).
- Antibodies directed to the 170 kDa subunit were capable of blocking surface adhesion to test cells (Petri, 1989). Therefore, the 170 kDa subunit is believed to be of primary importance in mediating adhesion, and is at times referred to as the 170 kDa adhesin.
- DNA molecules encoding both the heavy and light subunits have been cloned. The heavy and light subunits are encoded by distinct mRNAs (Mann, 1991), and these subunits have different amino acid compositions and N-terminal sequences.
- the present invention provides an Entamoeba histolytica lectin-based, LC3 subunit peptide vaccine, wherein the LC3 subunit peptide is present in an effective amount to induce mucosal anti-lectin IgA antibody production in a primate ⁇ e.g., a human) against Entamoeba histolytica or E. dispar.
- the LC3 -based subunit peptides that are used in the vaccine include portions of epitope 3 or epitope 7 of E. histolytica LC3 recombinant protein, which is a cysteine-rich protein of the lectin heavy subunit (amino acids 758-1134, numbering scheme consistent with Tannich, 1991).
- the E. histolytica LC3 subunit peptide vaccine is encoded by LC3 amino acids numbered 891-903 or 918-936, which are subunits of epitope 3 and by amino acids numbered 1114-1128 or 1128-1150, which are subunits of epitope 7.
- the vaccine may be in combination with a physiologically-acceptable, non-toxic vehicle and adjuvant.
- the LC3 subunit peptide is expressed from an isolated DNA sequence encoding the LC3 subunit peptide.
- the DNA encodes an LC3 subunit peptide containing contiguous amino acid residues from about residue 891 to about residue 903, from about residue 918 to about residue 936, from about residue 1114 to about residue 1128, or from about residue 1128 to about residue 1150.
- the LC3 subunit peptide is a variant of wild-type LC3 subunit peptide in that the variant LC3 subunit peptide has a modification at one or more amino acid residues. The modification may, for example, be a substitution at one or more amino acid residues (e.g., a conserved substitution).
- the vaccine may further contain an effective amount of an immunological adjuvant or other immune stimulating agent.
- at least one subunit peptide is conjugated or linked to a carrier molecule.
- one, two, three, four, five, or six peptides can be linked to a carrier molecule.
- These peptides can all be the same type of peptide, or can be different peptides.
- three subunit peptides containing amino acid residues 918-936 and three subunit peptides containing amino acid residues 1128-1150 may all be linked to a polylysine backbone.
- at least one of all four possible peptides is linked to the carrier molecule.
- the carrier molecule may, for example, be a polypeptide or a polysaccharide.
- the present invention also provides a method of protecting a susceptible a primate (e.g., a human) against E. histolytica or E. dispar colonization or infection by administering to the primate an effective amount of a vaccine containing an Entamoeba histolytica LC3 subunit peptide, wherein the LC3 subunit peptide is present in an effective amount to induce mucosal anti-lectin IgA antibody production in the primate, and wherein the LC3 subunit peptide is in combination with a physiologically-acceptable, non-toxic vehicle.
- the vaccine is administered by subcutaneous or intramuscular injection.
- the vaccine is administered by oral ingestion or intranasally.
- the present invention further provides an isolated and purified
- Entamoeba histolytica LC3 subunit peptide wherein the LC3 subunit peptide induces mucosal anti-lectin IgA antibody production in a primate against Entamoeba histolytica or E. dispar.
- the subunit peptide is Entamoeba histolytica epitope 3 (amino acids 868-944) or epitope 7 (amino acids 1114 to 1134).
- the subunit peptide is encoded by LC3 amino acids numbered 891-903, 918-936, 1114-1128, or 1128-1150.
- the present invention also provides an isolated and purified polynucleotide containing a nucleotide sequence encoding an E. histolytica LC3 subunit peptide, wherein the LC3 subunit peptide induces mucosal anti-lectin IgA antibody production in a primate against E. histolytica or E. dispar.
- the polynucleotide may be either DNA or RNA.
- the present invention also provides a purified antibody that specifically recognizes an LC3 subunit peptide that comprises contiguous amino acid residues from about residue 891 to about residue 903, from about residue 918 to about residue 936, from about residue 1114 to about residue 1128, or from about residue 1128 to about residue 1150.
- the antibody may be monoclonal, polyclonal and/or humanized.
- the invention is directed to both nucleic acid and immunological reagents that can be produced in view of the discovery of these peptides. These reagents are specific for each of the nucleic acids that encode the peptides, as well as their RNA or protein products.
- oligonucleotide probes specific for any one of these four peptides may be identified by one of ordinary skill in the art, using conventional nucleic acid probe design principles, by comparisons of the DNA sequences for these peptides.
- a method for immunizing a subject against Entamoeba histolytica or E. dispar infection by administering to the subject an effective amount of a vaccine as described above. Vaccination with the vaccine will result in an immune response that blocks the carbohydrate-binding activity of the amoeba, which is needed for both colonization and host cell killing.
- the present invention also provides methods of identifying further subunit peptides, using the techniques described in the Examples below.
- FIG. 1 Recombinant protein fragments produced from restriction enzyme digestion of LC3 DNA. Restriction enzymes sites are indicated, fragments are represented by their amino acid sequence numbers. Seven recombinant LC3 protein fragments (A through G) were produced.
- FIG. 2A ELISA OD results for serum anti-LC3 IgA ( Figure 2A) and IgG antibodies (Figure 2B) using purified LC3 antigen (means indicated by horizontal bar).
- Study groups include seronegative uninfected controls, asymptomatic, seropositive subjects with current E. histolytica infection as determined by fecal PCR, subjects recently cured of ALA with and without infection (by PCR), and ALA subjects free of infection by culture criteria one year after cure. There were substantially higher IgA and IgG antibody levels in recently cured ALA subjects with or without infection and seropositive subjects with asymptomatic intestinal infection, compared to controls and ALA subjects cured one year ago (p ⁇ 0.05 for each).
- FIG. 3 Recognition of LC3 epitopes by human anti-LC3 IgA and IgG antibodies and by anti-LC3 murine IgA monoclonal antibodies.
- IgA antibodies from ALA subjects infected or uninfected
- seropositive subjects with asymptomatic E. histolytica infection
- IgA antibodies from ALA subjects infected or uninfected
- seropositive subjects with asymptomatic E. histolytica infection
- Only anti-LC3 IgG antibodies recognized epitope six (open oval) which was lost only one year after cure of ALA.
- Anti- LC3 murine IgA monoclonal antibodies recognized epitopes 1, 2, 4, 5, and 6 (*) and not epitopes 2 or 7.
- Figure 4 Recognition by pooled human intestinal and serum anti-LC3 IgA antibodies of synthetic peptides based on the amino acid sequences of LC3 epitope 3 and 7. Ten overlapping peptides were synthesized based on the sequence of epitope 3 and two peptides based on epitope 7. Intestinal (triangles) and serum (circles) IgA antibodies were obtained from subjects cured of ALA with current infection (black); seropositive, asymptomatic PCR (+) subjects (gray) and seronegative PCR (-) control subjects (open symbols). Peptides 2, 9, 11, and 12 were recognized by intestinal and serum IgA antibodies from all subjects, compared to the cutoff point established by seronegative controls. Peptides 2, 9, and 11 were recognized by serum IgA antibodies from ALA subjects and fecal and serum IgA antibodies from asymptomatic infected seropositive subjects.
- FIG. 5 A graph demonstrating serum anti-LC3 IgG antibody response in baboons on days 7, 14, 21, and 28 following four intranasal vaccinations on days 1, 7, 14, and 21 with cholera toxin (20 ⁇ g), adjuvant alone (black bar), LC3-based peptide vaccine (amino acids 891-903, 918-936, 1114-1138, 1128- 1150 linked randomly, six molecules to a polylysine backbone; 200 ⁇ g) (light bar in middle), or purified 52 kdalton LC3 recombinant protein (200 ⁇ g) plus cholera toxin (20 ⁇ g) (shaded bar). Both the intranasal recombinant LC3 vaccine and the synthetic peptide vaccine induced serum IgG antibodies to the recombinant LC3 protein as determined by ELISA.
- FIG. 6 A graph showing serum anti-lectin IgG antibody responses in baboons on days 7, 14, 21, and 28 following four intranasal vaccinations on days 1, 7, 14, and 21 with cholera toxin (20 ⁇ g), adjuvant alone (black bar), LC3- based peptide vaccine (amino acids 891-903, 918-936, 1114-1138, 1128-1150 linked randomly, six molecules to a polylysine backbone; 200 ⁇ g) (light bar in middle), or purified 52 kDa LC3 recombinant protein (200 ⁇ g) plus cholera toxin (20 ⁇ g) (shaded bar).
- both the recombinant LC3 protein and the synthetic peptide vaccine induced serum IgG antibodies that recognized native Gal/GalNAC lectin from E. histolytica trophozoites, which is present on the surface of the parasite.
- Figure 7 A graph showing serum anti-peptide IgG antibody responses to in baboons on days 7, 14, 21, and 28 following four intranasal vaccinations on days 1, 7, 14, and 21 with cholera toxin (20 ⁇ g), adjuvant alone (black bar), LC3-based peptide vaccine (amino acids 891-903, 918-936, 1114-1138, 1128- 1150 linked randomly, six molecules to a polylysine backbone; 200 ⁇ g) (light bar in middle), or purified 52 kDa LC3 recombinant protein (200 ⁇ g) plus cholera toxin (20 ⁇ g) (shaded bar).
- cholera toxin 20 ⁇ g
- adjuvant alone black bar
- LC3-based peptide vaccine amino acids 891-903, 918-936, 1114-1138, 1128- 1150 linked randomly, six molecules to a polylysine backbone; 200 ⁇ g) (light bar in middle), or purified 52 kDa LC3
- Figure 9 A graph showing serum anti-lectin IgA antibody response in baboons on days 7, 14, 21, and 28 following four intranasal vaccinations on days 1, 7, 14, and 21 with cholera toxin (20 ⁇ g), adjuvant alone (black bar), LC3- based peptide vaccine (amino acids 891-903, 918-936, 1114-1138, 1128-1150 linked randomly, six molecules to a polylysine backbone; 200 ⁇ g) (light bar in . middle), or purified 52 kDa LC3 recombinant protein (200 ⁇ g) plus cholera toxin (20 ⁇ g) (shaded bar).
- the recombinant LC3 vaccine but not the synthetic peptide vaccine, induced serum anti-lectin IgA antibody response.
- Figure 10 A graph showing serum anti-peptide IgA antibody response in baboons on days 7, 14, 21, and 28 following four intranasal vaccinations on days 1, 7, 14, and 21 with cholera toxin (20 ⁇ g), adjuvant alone (black bar), LC3-based peptide vaccine (amino acids 891-903, 918-936, 1114-1138, 1128- 1150 linked randomly, six molecules to a polylysine backbone; 200 ⁇ g) (light bar in middle), or purified 52 kDa LC3 recombinant protein (200 ⁇ g) plus cholera toxin (20 ⁇ g) (shaded bar).
- cholera toxin 20 ⁇ g
- adjuvant alone black bar
- LC3-based peptide vaccine amino acids 891-903, 918-936, 1114-1138, 1128- 1150 linked randomly, six molecules to a polylysine backbone; 200 ⁇ g) (light bar in middle), or purified 52 kDa LC3
- FIG 11. A graph of fecal anti-LC3 IgA antibody response in baboons on days 7, 14, 21, and 28 following four intranasal vaccinations on days 1, 7, 14, and 21 with cholera toxin (20 ⁇ g), adjuvant alone (black bar), LC3 -based peptide vaccine (amino acids 891-903, 918-936, 1114-1138, 1128-1150 linked randomly, six molecules to a polylysine backbone; 200 ⁇ g) (light bar in middle), or purified 52 kDa LC3 recombinant protein (200 ⁇ g) plus cholera toxin (20 ⁇ g) (shaded bar).
- Figure 12 A graph showing fecal anti-lectin IgA antibody response in baboons on days 7, 14, 21, and 28 following four intranasal vaccinations on days 1, 7, 14, and 21 with cholera toxin (20 ⁇ g), adjuvant alone (black bar), LC3- based peptide vaccine (amino acids 891-903, 918-936, 1114-1138, 1128-1150 linked randomly, six molecules to a polylysine backbone; 200 ⁇ g) (light bar in middle), or purified 52 kDa LC3 recombinant protein (200 ⁇ g) plus cholera toxin (20 ⁇ g) (shaded bar).
- cholera toxin 20 ⁇ g
- adjuvant alone black bar
- LC3- based peptide vaccine amino acids 891-903, 918-936, 1114-1138, 1128-1150 linked randomly, six molecules to a polylysine backbone; 200 ⁇ g) (light bar in middle), or purified 52 kDa
- the synthetic peptide vaccine induced intestinal IgA antibodies that recognize the amebic native Gal/Gal/NAC lectin molecule present on the surface of the parasite; again, no mucosal IgA antibody response was observed with the LC3 recombinant protein vaccine.
- Figure 13 A graph showing fecal anti-peptide IgA antibody response in baboons on days 7, 14, 21, and 28 following four intranasal vaccinations on days 1, 7, 14, and 21 with cholera toxin (20 ⁇ g), adjuvant alone (black bar), LC3- based peptide vaccine (amino acids 891-903, 918-936, 1114-1138, 1128-1150 linked randomly, six molecules to a polylysine backbone; 200 ⁇ g) (light bar in middle), or purified 52 kDa LC3 recombinant protein (200 ⁇ g) plus cholera toxin (20 ⁇ g) (shaded bar).
- LC3- based peptide vaccine amino acids 891-903, 918-936, 1114-1138, 1128-1150 linked randomly, six molecules to a polylysine backbone; 200 ⁇ g) (light bar in middle), or purified 52 kDa LC3 recombinant protein (200 ⁇ g) plus cholera tox
- Immunity to Entamoeba species intestinal infection is associated with the presence of intestinal IgA antibodies to the parasite's galactose-inhibitable adherence lectin.
- the inventors determined the epitope specificity of serum and intestinal ⁇ i.e., mucosal) anti-lectin IgA antibodies by ELISA using overlapping fragments of a recombinant portion of the lectin heavy subunit, designated LC3. These findings were correlated with the effects of epitope-specific murine anti- lectin IgA monoclonal antibodies (MoAbs) on amebic in vitro galactose-specific adherence.
- MoAbs epitope-specific murine anti- lectin IgA monoclonal antibodies
- LC3 is a highly antigenic and immunogenic cysteine-rich protein (AA 758-1134) that includes the lectin's carbohydrate binding domain.
- the inventors also studied seropositive subjects that were currently infected with E. histolytica, disease-free, and asymptomatic.
- Serum anti-LC3 IgA antibodies from all study groups exclusively recognized the third (AA 868-944) and the seventh (AA 1114-1134) LC3 epitopes regardless of clinical status.
- Epitope six (AA 1070-1114) was also recognized by serum anti-LC3 IgG antibodies. However, IgG antibody recognition of epitope six, but not three or seven, was lost one year following cure of ALA. The inventors produced fourteen murine anti-LC3 IgA MoAbs that collectively recognize five of the seven LC3 epitopes. The majority of the murine MoAbs recognized the first epitope (AA 758-826), which was not recognized by human IgA antibodies. Interestingly, adherence of E. histolytica trophozoites to CHO cells was inhibited by MoAbs to epitopes one, three, four (AA 944-987), and six (p ⁇ .01).
- the LC3 epitopes recognized by human IgA antibodies were further characterized by use of overlapping synthetic peptides.
- the inventors identified four peptides (AA 891-903, 918- 936, 1114-1138, and 1128-1150) that in linear or cylized form were recognized by pooled intestinal IgA antibodies and serum IgG antibodies from ALA and asymptomatic, seropositive infected subjects.
- These lectin epitopes can be used in an amebiasis subunit vaccine designed to elicit mucosal immunity mimicking that of humans cured of ALA who are highly immune to new amebic infection (Ravdin et al., 2003).
- One or more subunits of the 170 kDa peptide are used as the active ingredient of a vaccine composition.
- the present invention provides peptides that are variants of LC3.
- a "variant" of LC3 is a polypeptide or oligopeptide LC3 that is not completely identical to native LC3.
- Variant LC3 molecules include peptides that are not full-length LC2 peptides, i.e., are subunits of LC3.
- Variant LC3 peptides can also be obtained by altering the amino acid sequence by insertion, deletion or substitution of one or more amino acid.
- the amino acid sequence of the protein is modified, for example by substitution, to create a polypeptide having substantially the same or improved qualities as compared to the native polypeptide.
- the substitution may be a conserved substitution.
- a "conserved substitution” is a substitution of an amino acid with another amino acid having a similar side chain.
- a conserved substitution would be a substitution with an amino acid that makes the smallest change possible in the charge of the amino acid or size of the side chain of the amino acid (alternatively, in the size, charge or kind of chemical group within the side chain) such that the overall peptide retains its spatial conformation but has altered biological activity.
- common conserved changes might be Asp to GIu, Asn or GIn; His to Lys, Arg or Phe; Asn to Gin, Asp or GIi and Ser to Cys, Thr or GIy.
- Alanine is commonly used to substitute for other amino acids.
- the 20 essential amino acids can be grouped as follows: alanine, valine, leucine, isoleucine, proline, phenylalanine, tryptophan and methionine having nonpolar side chains; glycine, serine, threonine, cystine, tyrosine, asparaginc and glutamine having uncharged polar side chains; aspartate and glutamate having acidic side chains; and lysine, arginine, and histidine having basic side chains.
- amino acid changes are achieved by changing the codons of the corresponding nucleic acid sequence. It is known that such polypeptides can be obtained based on substituting certain amino acids for other amino acids in the polypeptide structure in order to modify or improve antigenic or immunogenic activity. For example, through substitution of alternative amino acids, small conformational changes may be conferred upon a polypeptide that results in increased activity or enhanced immune response. Alternatively, amino acid substitutions in certain polypeptides may be used to provide residues that may then be linked to other molecules to provide peptide-molecule conjugates which retain sufficient antigenic properties of the starting polypeptide to be useful for other purposes. In one embodiment a poly lysine backbone may be used as a carrier for one or more of the same or different peptides of the present invention. For example, six peptides are linked to a single polylysine backbone.
- the LC3 peptide can be conjugated or linked to another peptide or to a polysaccharide.
- immunogenic proteins well known in the art, also known as “carriers,” may be employed.
- Useful immunogenic proteins include keyhole limpet hemocyanin (BCLH), bovine serum albumin (BSA), ovalbumin, human serum albumin, human gamma globulin, chicken immunoglobulin G and bovine gamma globulin.
- BCLH keyhole limpet hemocyanin
- BSA bovine serum albumin
- ovalbumin human serum albumin
- human gamma globulin human gamma globulin
- chicken immunoglobulin G bovine gamma globulin G
- bovine gamma globulin polysaccharides or proteins of other pathogens that are used as vaccines can be conjugated to, linked to, or mixed with the LC3 peptide such as tetnus toxoid.
- hydropathic index of amino acids in conferring interactive biological function on a polypeptide, wherein it is found that certain amino acids may be substituted for other amino acids having similar hydropathic indices and still retain a similar biological activity.
- substitution of like amino acids may be made on the basis of hydrophilicity, particularly where the biological function desired in the polypeptide to be generated in intended for use in immunological embodiments.
- the greatest local average hydrophilicity of a "protein,” as governed by the hydrophilicity of its adjacent amino acids correlates with its immunogenicity. Accordingly, it is noted that substitutions can be made based on the hydrophilicity assigned to each amino acid. In using either the hydrophilicity index or hydropathic index, which assigns values to each amino acid, the substitutions of amino acids are at values of ⁇ 2, such as at ⁇ 1, or at ⁇ 0.5.
- the variant LC3 peptide has at least 50%, at least about 80%, and at least about 90% or even 100% contiguous amino acid sequence homology or identity to the amino acid sequence of a corresponding native LC3.
- the amino acid sequences of the LC3 peptides correspond essentially to portions of the native LC3 amino acid sequence.
- “correspond essentially to” refers to a polypeptide sequence that will elicit a protective immunological response.
- An immunological response to a composition or vaccine is the development in the host of a cellular and/or antibody-mediated immune response to the polypeptide or vaccine of interest. Usually, such a response consists of the subject producing antibodies, B cell, helper T cells, suppressor T cells, and/or cytotoxic T cells directed specifically to an antigen or antigens included in the composition or vaccine of interest.
- a variant of the invention may include amino acid residues not present in the corresponding native LC3 or deletions relative to the corresponding native LC3.
- the LC3 peptides of the vaccine may be expressed from isolated DNA sequences encoding the LC3 peptides.
- "Recombinant” is defined as a peptide or nucleic acid produced by the processes of genetic engineering.
- the terms "protein,” “peptide” and “polypeptide” are used interchangeably herein.
- Nucleic acid molecules encoding amino acid sequences encoding an LC3 peptide are prepared by a variety of methods known in the art. These methods include, but are not limited to, isolation from a natural source (in the case of naturally occurring amino acid sequence variants) or preparation by oligonucleotide-mediated (or site-directed) mutagenesis, PCR mutagenesis, and cassette mutagenesis of an earlier prepared variant or a non-variant version of the LC3 peptide.
- Variant peptides may be conveniently prepared by direct chemical synthesis on solid phase supports and their subsequent separation from the support. Such methods are well known in the art.
- a "chemical derivative" of the 170-kDa subunit contains additional chemical moieties not normally a part of the peptide. Covalent modifications of the peptide are included within the scope of this invention. Such modifications may be introduced into the molecule by reacting targeted amino acid residues of the peptide with an organic derivatizing agent that is capable of reacting with selected side chains or terminal residue
- the present vaccine compositions are used for prevention of E. histolytica infection in subjects at risk for such an infection.
- Subunits of the 170-kDa protein can be used as immunogens. Since the epitope-bearing fragments are relatively short, for example containing 20 amino acids or less, it is advantageous to couple the peptide to an immunogenic carrier to enhance its immunogenicity.
- Such coupling techniques are well known in the art, and include standard chemical coupling techniques using linker moieties such as those available from Pierce Chemical Company, Rockford, 111.
- Suitable carriers are proteins such as keyhole limpet hemocyanin (KLH), E. coli pilin protein k99, BSA, or rotavirus VP6 protein.
- the LC3 peptide vaccine can be administered by subcutaneous or intramuscular injection.
- the vaccine can be administered by oral ingestion or intranasal inoculation.
- the LC3 peptide may be administered parenterally, usually by intramuscular or subcutaneous injection in an appropriate vehicle.
- Other modes of administration however, such as oral delivery or intranasal delivery, are also acceptable.
- Vaccine formulations will contain an effective amount of the active ingredient in a vehicle. The effective amount is sufficient to prevent, ameliorate, or reduce the incidence of E. histolytica colonization in the target mammal. An effective amount to be administered in a vaccine dose is readily determined by one skilled in the art.
- the active ingredient may typically range from about 1% to about 95% (w/w) of the composition, or even higher or lower if appropriate.
- the quantity to be administered depends upon factors such as the age, weight, and physical condition of the animal or the human subject considered for vaccination. The quantity also depends upon the capacity of the animal's immune system to synthesize antibodies, and the degree of protection desired. Effective dosages can be readily established by one of ordinary skill in the art through routine trials establishing dose response curves.
- the subject is immunized by administration of the LC3 peptide in one or more doses. Multiple doses may be administered as is required to maintain a state of immunity to E. histolytica.
- Intranasal formulations may include vehicles that neither cause irritation to the nasal mucosa nor significantly disturb ciliary function.
- Diluents such as water, aqueous saline or other known substances can be employed with the subject invention.
- the nasal formulations may also contain preservatives such as, but not limited to, chlorobutanol and benzalkonium chloride.
- a surfactant may be present to enhance absorption of the subject proteins by the nasal mucosa.
- Oral liquid preparations may be in the form of, for example, aqueous or oily suspension, solutions, emulsions, syrups, or elixirs, or may be presented dry in tablet form or a product for reconstitution with water or other suitable vehicle before use.
- Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), or preservative.
- the LC3 peptide can be isolated, lyophilized and stabilized.
- the LC3 peptide may then be adjusted to an appropriate concentration, optionally combined with a suitable vaccine adjuvant, and packaged for use.
- suitable adjuvants include but are not limited to surfactants, e.g., hexadecylamine, octadecylamine, lysolecithin, dimethyldioctadecylammonium bromide, N,N-dioctadecyl-N'-N-bis(2- hydroxyethyl-propane di-amine), methoxyhexadecyl-glycerol, and pluronic polyols; polanions, e.g., pyran, dextran sulfate, poly IC, polyacrylic acid, carbopol; peptides, e.g., muramyl dipeptide, MPL, aimethylglycine,
- the immunogenic product may be incorporated into liposomes for use in a vaccine formulation, or may be conjugated to proteins such as keyhole limpet hemocyanin (KLH) or human serum albumin (HSA) or other polymers.
- KLH keyhole limpet hemocyanin
- HSA human serum albumin
- LC3 peptides for vaccination of a mammal against amebic colonization offers advantages over other vaccine candidates. Prevention of colonization or infection by inoculation not only reduces the incidence of the immediate symptoms, but also eliminates sequelae.
- the active ingredient or mixture of active ingredients, in the vaccine composition is formulated conventionally using methods well known for formulation of protein or peptide vaccines.
- Vaccine compositions may include an immunostimulant or adjuvant such as complete or incomplete Freund's adjuvant, aluminum hydroxide, liposomes, beads such as latex or gold beads, ISCOMs, and the like.
- Liposomes are pharmaceutical compositions in which the active protein is contained either dispersed or variously present in corpuscles consisting of aqueous concentric layers adherent to lipidic layers.
- the active protein is preferably present in the aqueous layer and in the lipidic layer, inside or outside, or, in any event, in the non-homogeneous system generally known as a liposomic suspension.
- the hydrophobic layer, or lipidic layer generally, but not exclusively, comprises phospholipids such as lecithin and sphingomyelin, steroids such as cholesterol, more or less ionic surface active substances such as dicetylphosphate, stearylamine or phosphatidic acid, and/or other materials of a hydrophobic nature.
- the vaccine compositions preferably contain (1) an effective amount of the active ingredient, that is, the peptide or peptides, together with (2) a suitable amount of a carrier vehicle, and, if desired, (3) preservatives, buffers, and the like.
- peptide vaccines are administered as is generally understood in the art.
- suitable formulation peptide vaccines may be administered across the mucus membrane using penetrants such as bile salts or fusidic acids in combination, usually, with a surfactant.
- Transcutaneous administration of peptides is also known.
- Oral formulations can also be used. Dosage levels depend on the mode of administration, the nature of the subject, and the nature of carrier/adjuvant formulation.
- an effective amount of the protein or peptide is between about 0.01 ⁇ g/kg-1 mg/kg body weight.
- multiple administrations of the vaccine in a standard immunization protocol are used, as is standard in the art.
- antibody encompass intact molecules as well as fragments thereof that are capable of binding to LC3 subunit peptide.
- Antibodies can be polyclonal antibodies, monoclonal antibodies, humanized or chimeric antibodies, single chain Fv antibody fragments, Fab fragments, and F(ab) 2 fragments.
- Polyclonal antibodies are heterogeneous populations of antibody molecules that are specific for a particular antigen, while monoclonal antibodies are homogeneous populations of antibodies to a particular epitope contained within an antigen.
- An antibody can be of any immunoglobulin (Ig) class, including IgM, IgA, IgD, IgE, and IgG, and any subclass thereof.
- Antibodies of the IgA class are particularly useful because one antibody molecule can cross-link another of LC3 subunit peptide, and are mucosal antibodies.
- Immune complexes containing Ig molecules that are cross-linked (e.g., cross-linked IgG) and are thus multivalent also are capable of cross-linking a plurality of LC3 subunit peptide molecules, and can be particularly useful.
- an “epitope” is a portion of an antigenic molecule to which an antibody binds. Antigens can present more than one epitope at the same time. For polypeptide antigens, an epitope typically is about four to six amino acids in length. Two different immunoglobulins can have the same epitope specificity if they bind to the same epitope or set of epitopes.
- Monoclonal antibodies are contained in the sera of immunized animals.
- Monoclonal antibodies can be prepared using, for example, standard hybridoma technology.
- monoclonal antibodies can be obtained by any technique that provides for the production of antibody molecules by continuous cell lines in culture as described in the art.
- a hybridoma producing monoclonal antibodies of the invention can be cultivated in vitro or in vivo.
- Antibodies of the invention also can be isolated from, for example, the serum of an individual. Suitable methods for isolation include purification from mammalian serum using techniques that include, for example, chromatography.
- Antibodies that bind to LC3 subunit peptides also can be produced by, for example, immunizing host animals (e.g., rabbits, chickens, mice, guinea pigs, or rats) with LC3 subunit peptides.
- host animals e.g., rabbits, chickens, mice, guinea pigs, or rats
- An LC3 peptide or a portion of an LC3 peptide can be produced recombinantly, by chemical synthesis, or by purification of the native protein, and then used to immunize animals by injection of the polypeptide.
- Adjuvants can be used to increase the immunological response, depending on the host species.
- Suitable adjuvants include Freund's adjuvant (complete and incomplete), mineral gels such as aluminum hydroxide, surface-active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin (KLH), and dinitrophenol. Standard techniques can be used to isolate antibodies generated in response to the LC3 immunogen from the sera of the host animals. Antibodies can be produced recombinantly.
- the amino acid sequence (e-g; the partial amino acid sequence) of an antibody provided herein can be determined by standard techniques, and a cDNA encoding the antibody or a portion of the antibody can be isolated from the serum of the subject (e.g., the human patient or the immunized host animal) from which the antibody was originally isolated.
- the cDNA can be cloned into an expression vector using standard techniques.
- the expression vector then can be transfected into an appropriate host cell (e.g., a Chinese hamster ovary cell, a COS cell, or a hybridoma cell), and the antibody can be expressed and purified.
- Antibody fragments that have specific binding affinity for LC3 subunit peptides and retain cross-linking function also can be generated by techniques such as those disclosed above.
- Such antibody fragments include, but are not limited to, F(ab') 2 fragments that can be produced by pepsin digestion of an antibody molecule, and Fab fragments that can be generated by reducing the disulfide bridges of F(ab') 2 fragments.
- Fab expression libraries can be constructed. Single chain Fv antibody fragments are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge
- Single chain Fv antibody fragments can be produced through standard techniques, such as those disclosed in U.S. Patent No. 4,946,778. Such fragments can be rendered multivalent by, for example, biotinylation and cross-linking, thus generating antibody fragments that can cross-link a plurality of LC3 subunit peptides.
- the invention will now be illustrated by the following non-limiting Examples.
- Serum anti- LC3 IgG and IgA antibodies exclusively recognized the third (868-944) and the seventh (1114-1134) LC3 epitopes.
- a sixth epitope (1070-1114) was identified by anti-LC3 IgG antibodies, but not by IgA antibodies.
- Mouse anti-LC3 IgA MoAbs recognized five out of seven LC3 fragments. The majority of the murine MoAbs recognized the first LC3 fragment (758-826), but was not recognized by human immune sera.
- adherence of E. histolytica in vitro to CHO cells was inhibited by a MoAb to the third fragment (61%), but not by a MoAb to the sixth fragment (28%).
- the third fragment of LC3 induces a humoral immune response (IgA and IgG) in humans with ALA or asymptomatic infection without variation among individuals.
- MoAb against this fragment inhibits the in vitro lectin-mediated adherence of E. histolytica to mammalian cells, suggesting this fragment might be a successful vaccine candidate for inducing mucosal immunity to E. histolytica infection.
- Colonization of the gut by the enteric protozoan, E. histolytica is associated with adherence to the carbohydrate-rich mucin layer covering the colonic mucosa (Chadee, 1987; Chadee, 1988), which forms a non-immune barrier to parasitic invasion.
- secretory IgA antibodies are thought to contribute to mucosal defense via immune exclusion. IgA antibodies prevent contact of enteric pathogens with the intestinal epithelial surface due to their agglutination, entrapment within immune complexes, and clearance within the mucous blanket (McGhee, 1992).
- Adherence of E. histolytica to colonic mucins and epithelial cells is mediated by the parasite's galactose-inhibitable surface lectin (Chadee, 1987; Petri, 1987).
- the carbohydrate-binding domain of the lectin's 170 kDa heavy subunit (Petri, 1990; Ravdin, 1981) is localized between amino acids 895 to 998 (Dodson, 1997; Mann, 1993; Pillai, 1999).
- Murine IgG monoclonal antibodies to the 170 kDa lectin subunit (Petri, 1987) completely abrogate the galactose- specific adherence of E.
- dispar lectin includes the complete carbohydrate-binding domain (Pillai, 1997). E. dispar induces an intestinal but not a humoral anti-lectin IgA antibody response (Ravdin, 2003).
- a recombinant cysteine-rich fusion protein that includes amino acids
- Anti-LC3 IgA and IgG antibodies are present in the sera of over 90% of patients with invasive amebiasis (colitis and ALA) and in the majority of subjects with asymptomatic E. histolytica intestinal infection (Abd-Alla, 2002; Ravdin, 2003). In several studies that encompassed large numbers of patients with amebic colitis or liver abscess, a mucosal IgA immune response to the recombinant LC3 antigen was detected (Abou-El-Magd, 1996; Ravdin, 2003). The present inventors identified the specific LC3 epitopes recognized by
- IgA antibodies associated with the putatively protective mucosal immune response that occurs following cure of ALA (Ravdin, 2003).
- the IgA antibody epitopes were identified by use of overlapping recombinant LC3 protein fragments, utilizing serum IgG antibodies for comparison. The findings were confirmed by studies with pooled intestinal IgA antibodies.
- the inventors produced IgA monoclonal antibodies to the LC3 protein for use as specific probes to correlate epitope-recognition with inhibition of amebic galactose- specif ⁇ c adherence.
- overlapping peptides were prepared utilizing amino acid sequences of the reactive LC3 epitopes and screened for recognition using IgA antibodies from pooled human sera and feces.
- the Taq Polymerase (Amersham Pharmacia Biotech, Catalog # 270799) was diluted as 1:20 immediately before use.
- E. histolytica sense primer (5'- GTA CAA AAT GGC CAA TTC ATT CAA CG - 3' (SEQ ID NO: I)
- E. dispar sense primer (5' - GTA CAA AGT GGC CAA TTT ATG TAA GCA - 3' (SEQ ID NO:2)
- E. histolytica! E. dispar anti-sense primer (5 ' - GAA TTG ATT TTA CTC AAC TCT AGA G - 3' (SEQ ID NO:3)) (Blessman, 2002) were prepared as 10 Pmol/ ⁇ l.
- Bovine Serum Albumin (BSA) (Pierce, 200 mg/ml, Catalog # 23210) was diluted with equal volume OfH 2 O (500 Tl BSA + 500 ⁇ l H 2 O) and kept at 4 0 C.
- the DNA to be tested (5 ⁇ l) was added to the 95 ⁇ l of PCR mixture to complete 100 ⁇ l. Each DNA sample was tested twice, once using E. histolytica sense and once using E. dispar sense.
- the conventional PCR machine thermocycling conditions were one cycle of 2 minutes at 95°C followed by 35 cycles of 1 minute at 94°C, 1 minute at 56 0 C, and 30 seconds at 72 0 C. The last single cycle occurred for 3 minutes at 72 0 C.
- mice Maine that maintains pathogen-free animal colonies.
- the mice were maintained in micro-isolation cages, free from Sendai virus and other pathogenic microorganisms.
- IgA monoclonal antibodies were produced via a mucosal immunization protocol.
- BALB/c mice were immunized intra-Peyers patch twice with 200 ⁇ g of LC3 protein and boosted intravenously with 2 ⁇ g epinephrine IP and 50 ⁇ g of LC3 protein the following day. Three days later, the mice were scarified and their spleen cells hybridized to SP2/0 myeloma cells.
- Immune plates were coated overnight with LC3 protein at 4 0 C at pH 9.6. The plates were blocked with 1% BSA in phosphate-buffered saline solution (PBS). Tissue culture supernatants from each fusion were incubated for one hour at room temperature or over-night at 4 0 C. Following washing with PBS containing 1% BSA and 0.5% Tween 20, alkaline phosphatase conjugated goat anti-mouse IgA antibodies were added as 100 ⁇ l/well at a concentration of 1 to 1000 in PBS- Tween with 1% BSA. The enzymatic reaction was developed with 1 mg/ml of p-nitophenol phosphate substrate and the optical density (OD) was determined at a wavelength of 410 ⁇ m.
- PBS phosphate-buffered saline solution
- ELISA was performed as described previously (Abd-Alla, 2000). LC3 protein fragments were purified as described (Soong, 1995). Briefly, 96-well microtiter flat-bottomed polystyrene ELISA plates were coated with individual LC3 protein fragments (0.4 Tg/well) and the non-reactive sites were blocked with 1% BSA. Serum samples were studied at a 1 : 100 dilution for IgA and 1:250 for IgG, all in PBS-Tween - 1% BSA and incubated for 2 hours at room temperature.
- Alkaline phosphatase-conjugated goat anti-human IgA antibodies (ICN Biomedicals (Costa Mesa, California) or anti-human IgG (SIGMA, St. Louis, MO) were diluted (at 1 :2500 for IgA and 1 :5000 for IgG) in PBS-Tween - 1% BSA for incubation in 100 ⁇ l well for 2 hours at room temperature. Developing, reading the plates and correction of nonspecific background binding were performed as described (Ravdin, 1990).
- Transformed bacteria (Soong, 19959) were pelleted, lysed in SDS, and loaded into 10% Laemmli polyacrylamide gels. After electrophoresis, the proteins were transferred to nitrocellulose papers for immunoblotting with anti- LC3 IgA monoclonal antibodies.
- Horseradish peroxidase-conjugated anti-mouse IgA (1 : 1000 dilution) was utilized as a secondary antibody and 4-chloro-l naphthol as substrate for staining of the bound secondary antibody.
- strain HMI:IMSS were maintained in axenic culture utilizing TYI-S-33 culture medium, as described by Diamond (Diamond, 1993), and harvested as described previously (Ravdin, 1981).
- CHO cells obtained from the ATCC were grown in F- 12 medium (GIBCO) supplemented with 10% fetal bovine sera (GIBCO), penicillin (100 ⁇ g/ml) and streptomycin (100 ⁇ g/ml) as described previously.
- the LC3 protein encompasses amino acid 758 to 1134 of the lectin heavy subunit.
- LC3 DNA was cleaved by restriction enzyme digestion into two fragments (A and D) encoding proteins of: AA 758 - 944 and 944 - 1134.
- Fragment A was further digested into fragments B encoding (AA 758 - 868) and C (AA 758-826) ( Figure 1).
- Fragment D was further digested into fragments E, F, and G encoding proteins of AA 944-1114, 944-1070, and 944-987, respectively.
- Recombinant proteins were produced from each of these overlapping DNA fragments, the pattern of their recognition by IgA antibodies allowed identification of seven distinct LC3 epitopes.
- Seropositive subjects with asymptomatic infection had levels of anti-LC3 IgA and IgG antibodies comparable to that of the recently cured ALA subjects ( Figures 2A and 2B).
- Serum anti-LC3 IgG antibody ELISA OD values (at equal dilutions) were higher than those for IgA antibodies (p ⁇ 0.05).
- nonpurified recombinant proteins present in cell supernate were utilized as antigen in the ELISA. Therefore, nonpurified LC3 recombinant protein present in E. coli supernate served as the positive control under identical experimental conditions as the recombinant LC3 fragments.
- a- Seronegative or seropositive is defined by ELISA to purified LC3 protein, nonpurified LC3 protein serves as a positive control for nonpurif ⁇ ed LC3 protein fragments, b- P ⁇ .05 for recognizing LC3 fragment A compared to LC3 fragments B, C, E, F, and G. c- P ⁇ .05 for recognizing LC3 fragment D compared to LC3 fragments B, C, E, F, and G.
- Serum IgA antibodies obtained from all four amebiasis study groups recognized only LC3 fragments A (AA 758-944) and D (AA 944-1134), Table 1, (p ⁇ 0.05 compared to all other fragments and sera from uninfected seronegative controls).
- ELISA for anti-LC3 serum IgG antibodies demonstrated a higher level of reactivity than IgA to the nonpurified LC3 in E. coli supernate (81% to 100%, Table X), concordant with the higher OD readings for serum IgG antibodies to the purified LC3 protein ( Figure 2B).
- Serum IgG antibodies from three of the four amebiasis subgroups (asymptomatically infected, ALA infected, ALA uninfected) recognized fragments A (AA 758-944), D (AA 944-1134) and E (AA 944-1114) (p ⁇ 0.05, Table 2).
- IgG antibody recognition of fragment E was absent in sera from uninfected ALA subjects only one year after cure (Table 2).
- a - Seronegative or seropositive is defined by ELISA to purified LC3 protein, nonpurified LC3 protein serves as a positive control for nonpurified LC3 protein fragments.
- d - P ⁇ .05 for recognizing LC3 fragment E compared to LC3 fragments B, C, F, and G. e - P ⁇ .05 for recognizing fragment E compared to other ALA subjects and asymptomatic seropositive controls.
- the inventors screened 1300 hybridoma clones by ELISA for anti-LC3 IgA antibodies and found 85 positive secretors. Of the 85, by limiting dilution, the inventors found 14 that were stable as single clones. The inventors confirmed by immunoblotting whether the 14 hybridoma clones produced IgA monoclonal antibodies to LC3 protein (Table 3). All but 2 of the 14 monoclonal antibodies, numbers 244 and 728, recognized native E. histolytica lectin by ELISA. IgA monoclonal antibodies to Sendai virus served as a negative control in all experiments.
- Anti-LC3 IgA monoclonal antibodies were further characterized by epitope mapping as shown in Table 3.
- the seven LC3 protein fragments (A-G) were immunoblotted with all 14 of the IgA monoclonal antibodies; the LC3 protein and a LCl fusion protein (AA 1-346) were used as positive and negative controls respectively.
- Eight monoclonal antibodies (numbers 38, 41, 193, 244, 606, 728, 737, and 854) recognized fragments A, B, and C. Clone 875 reacted only with fragment A, indicating it recognized epitope 3 (AA 868-944).
- the inventors determined by similar analysis the epitope specificity of each anti-LC3 IgA monoclonal antibody (summarized in Table 3 and illustrated in Figure 3). None of the IgA monoclonal antibodies were found to recognize the second or seventh LC3 epitopes (AA 826-868 and 1114-1134) ( Figure 2). Interestingly, the overwhelming majority (13 of 14) of the murine IgA monoclonal antibodies recognized LC3 epitopes not recognized by human anti-LC3 IgA antibodies (Table 3 and Figure 3).
- a Percent inhibition of adherence defined as comparison to control test medium without antibodies present.
- Peptide # 2 (AA 891-903) (TGT ACA TAC GAA ATA ACA ACA AGA GAA TGT AAA ACA TGT (SEQ ID NO: 4), CTYEITTRECKTC (SEQ ID NO:5)); Peptide # 9, (AA 918-936) (TGT GCA GAA GAG ACT AAG AAT GGA GGA GTT CCA TTC AAA TGT AAG AAT AAC AAT TGC (SEQ ID NO:6), CAEETKNGGVPFKCKNNNC (SEQ ID NO:7);
- LC3 epitopes recognized by human serum and intestinal IgA antibodies regardless of clinical status are AA 891-903 and AA 918-936 of epitope three and all of epitope seven (AA 1114-1150).
- LC3 (and epitope 7) ends at AA 1134, but Peptide # 12 continues on to AA 1150.
- Immunity was reported to relate to individuals possessing anti-CRD (LC3 AA 895 to 998) IgA antibodies in feces (Haque, 2001). Those with other anti-lectin IgA antibodies were reported not to be immune (Haque, 2002). However, these IgA antibodies were demonstrated to be present in children for a very short time (one month) (Haque, 2001; Haque, 2002). Following cure of ALA in Durban, South Africa, protective immunity to E. dispar infection persists for at least three years, ALA subjects demonstrated sustained secretion of high titer intestinal anti-lectin IgA antibodies for up to 36 months (Ravdin, 2003).
- the inventors determined that serum IgA antibodies from asymptomatically infected subjects, seropositive ALA subjects (with or without current E. histolytica infection), and uninfected ALA subjects one year after cure exclusively recognized LC3 epitopes 3 (AA 868-944) and 7 (AA 1114-1134).
- Serum anti-LC3 IgG antibodies from recently cured ALA subjects also recognized epitope six (AA 1070-1114), but this reactivity was lost by one year. There was no difference in epitope recognition between ALA subjects with or without sustained intestinal infection. This suggests that immunity to new asymptomatic Entamoeba species infection as observed by Haque et al.
- Haque, 2002 and Ravdin et al. does not correlate with the ability to clear an established infection.
- Haque, 2002 the present inventors found no clinical or immunologic subgroup that demonstrates a unique lectin epitope recognition pattern.
- the inventors cannot rule out the presence of additional IgA lectin epitopes that were not identified due to the sensitivity of the assay, clearly, epitopes three and seven were immuno- dominant.
- previous studies indicate that the titer of anti-lectin IgA in stool may be the strongest predictor of effective mucosal immunity in adults (Ravdin, 2003). Infection by E.
- dispar does induce an intestinal anti-lectin IgA response, but it is of low titer and short lived (Ravdin, 2003). Therefore, it is not surprising that despite multiple shared lectin epitopes (Petri, 1990), E. dispar infection does not induce cross-species protection against E, histolytica (Ravdin, 2003).
- the present inventors utilized murine anti-LC3 IgA monoclonal antibodies as epitope-specific probes to correlate in vitro adherence-inhibitory activity with human IgA epitope specificity.
- immunization of BALB/c mice raised antibodies mainly to LC3 epitopes that are not recognized by humans (epitopes 1, 4, and 5 with epitope 1 predominate).
- Only one of fourteen murine IgA antibodies recognized an epitope shared by human IgA antibodies (epitope 3).
- vaccine studies using lectin-derived proteins in murine experimental models must be interpreted with caution due to clear differences in MHC-restricted immune recognition of the lectin protein structure. It would seem unwise to jump directly from murine models to studies in humans without conducting vaccine studies in a more immunologically related model, such as primates.
- Murine IgA monoclonal antibodies possessed adherence-inhibitory activity against amebic native surface lectin regardless of which LC3 epitope the antibody recognized. Interestingly, no adherence-enhancing activity (Petri, 1990) was observed with any of the IgA monoclonal antibodies studied. Analogous to studies of murine IgG or IgM anti-lectin monoclonal antibodies (Petri, 1987), adherence inhibitory activity of these IgA antibodies did not correlate with direct recognition of the carbohydrate binding domain (AA 895- 998) (Dodson, 1997; Mann, 1993; Pillai, 1999), which is contained within epitope four and extends partially to epitopes three and five. Therefore, the ability of anti-lectin IgA antibodies to mediate immunity in the gut may relate to multiple factors important in forming immune complexes and preventing the parasite from binding to colonic mucins or host cells.
- the LC3 protein does not include the lectin's pseudo-repeat region (AA 436-624), to which Lotter et al. (Lotter, 1997) raised adherence-inhibitory antibodies.
- the LC3 protein includes the parasite's carbohydrate binding domain (Dodson, 1997; Pillai, 1999), is sufficient to induce immunity to ALA in gerbils (Soong, 1995) (as is a smaller 375 amino acid fragment of LC3 (Dodson, 1999)), the inventors chose this cysteine rich recombinant protein for further study. It is possible that IgA antibodies to the pseudo-repeat region may also be important in host mucosal immunity.
- E. histolytica is the third leading parasitic cause of death worldwide. Recent field studies indicate that following cure of invasive amebiasis, intestinal IgA antibodies to the amebic galactose-inhibitable lectin provide immunity to new E. histolytica and E. dispar infections.
- the recombinant LC3 protein is a cysteine-rich protein (AA 758 to 1134) of the lectin heavy subunit that includes the carbohydrate-binding domain, is highly antigenic, and effective as a subunit vaccine in the gerbil model of amebic liver abscess.
- AA 918-936 TGT GCA GAA GAG ACTAAGAAT GGA GGA GTT CCA TTC AAA TGT AAG AAT AAC AAT TGC (SEQ ID NO:6), CAEETKNGGVPFKCKNNNC (SEQ ID NO:7)
- AA 1128-1150 TGT ACT GTT TCA GAA GAA TTC CCAACAATC ACA CCAAAT CAA GGAAGA TGT TTC TAT TGT CAA TGT TCA (SEQ ID NO: 10), CTVSEEFPTITPNQGRCFYCQCS (SEQ ID NO: 11)
- Synthetic peptides produced to mimic these from epitopes were randomly linked to a polylysine backbone (6 peptides per molecule) and administered to baboons intranasally (400 ⁇ g) x 4 at seven-day intervals with cholera holotoxin (20 ⁇ g) as adjuvant, the recombinant LC3 protein served as a positive control.
- the inventors found that the intranasal lectin-based synthetic peptide vaccine induced anti-peptide, anti-LC3, and anti-lectin (purified native protein) intestinal IgA and serum IgG antibodies by day 28 of the vaccine protocol. In contrast, the recombinant LC3 protein vaccine induced serum anti-
- LC3 and anti-lectin IgA and IgG antibody responses did not elicit any intestinal anti-lectin IgA antibody response.
- the LC3 vaccine- elicited serum IgA and IgG antibodies did not recognize any of the four putatively protective LC3 epitopes as defined by IgA antibody ELISA with human serum and feces.
- the inventors developed an intranasal synthetic peptide amebiasis subunit vaccine that elicited a mucosal IgA antibody response in baboons that mimics that of humans cured of invasive amebiasis.
- Group 1 3 baboons CT (20 ⁇ g in 100 ⁇ l) + saline (100 ⁇ l) in each nostril (200 ⁇ l total) as a negative control;
- Group 2 3 baboons CT (20 ⁇ g in 100 ⁇ l) + 400 ⁇ g peptide mixture in 100 ⁇ l saline in each nostril (200 ⁇ l total); and Group 3: 3 baboons CT (20 ⁇ g in 100 ⁇ l) + 200 ⁇ g LC3 (200 ⁇ g) in 100 ⁇ l saline in each nostril (200 ⁇ l total) as a positive control.
- both the intranasal recombinant LC3 vaccine and the synthetic peptide vaccine induced serum IgG antibodies to the recombinant LC3 protein as determined by ELISA ( Figure 5).
- both the recombinant LC3 protein and the synthetic peptide vaccine induced serum IgG antibodies that recognized native Gal/GalNAC lectin from E. histolytica trophozoites, which is present on the surface of the parasite ( Figure 6).
- Mucosal anti-lectin IgA antibodies provided effective immunity against E. histolytica and E. dispar infections. The frequency of E. histolytica and E. dispar infection in endemic areas is greater than previously reported, eliciting amnestic intestinal anti-lectin IgA antibody responses.
- serum and intestinal IgA antibodies from subjects in Durban, S. Africa recognize four discrete LC3 epitopes. Based on the LC3 epitope amino acid sequence, an experimental synthetic peptide vaccine delivered intranasally with cholera toxin as adjuvant to baboons induced an intestinal anti-peptide, anti-LC3, and anti-lectin IgA antibody response. It is important to note that only the peptide vaccine, and not the recombinant LC3 vaccine, induces serum and intestinal IgA antibodies to the four putatively protective epitopes.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2005800279983A CN101052412B (en) | 2004-06-18 | 2005-06-16 | Amebiasis subunit vaccine |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58124804P | 2004-06-18 | 2004-06-18 | |
US60/581,248 | 2004-06-18 | ||
US58157704P | 2004-06-21 | 2004-06-21 | |
US60/581,577 | 2004-06-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006009862A2 true WO2006009862A2 (en) | 2006-01-26 |
WO2006009862A3 WO2006009862A3 (en) | 2006-06-15 |
Family
ID=35785704
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/021507 WO2006009862A2 (en) | 2004-06-18 | 2005-06-16 | Amebiasis subunit vaccine |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN101052412B (en) |
WO (1) | WO2006009862A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107629112B (en) * | 2017-09-07 | 2020-10-27 | 北京大学 | High-affinity LC3 protein targeting peptide and application thereof |
-
2005
- 2005-06-16 CN CN2005800279983A patent/CN101052412B/en not_active Expired - Fee Related
- 2005-06-16 WO PCT/US2005/021507 patent/WO2006009862A2/en active Application Filing
Non-Patent Citations (5)
Title |
---|
ABD-ALLA MOHAMED D ET AL: "Identification of the Entamoeba histolytica galactose-inhibitable lectin epitopes recognized by human immunoglobulin A antibodies following cure of amebic liver abscess." INFECTION AND IMMUNITY. JUL 2004, vol. 72, no. 7, July 2004 (2004-07), pages 3974-3980, XP002369814 ISSN: 0019-9567 * |
MANN B J ET AL: "MOLECULAR ANALYSIS OF THE GAL/GALNAC ADHESIN OF ENTAMOEBA HISTOLYTICA" JOURNAL OF EUKARYOTIC MICROBIOLOGY, LAWRENCE, KS, US, vol. 45, no. 2, March 1998 (1998-03), pages 13S-16S, XP008008340 ISSN: 1066-5234 * |
PILLAI D R ET AL: "Entamoeba dispar: molecular characterization of the galactose/N-acetyl-d-galactosamine lectin." EXPERIMENTAL PARASITOLOGY. DEC 2001, vol. 99, no. 4, December 2001 (2001-12), pages 226-234, XP002369816 ISSN: 0014-4894 * |
SOONG C J ET AL: "A recombinant cysteine-rich section of the Entamoeba histolytica galactose-inhibitable lectin is efficacious as a subunit vaccine in the gerbil model of amebic liver abscess." THE JOURNAL OF INFECTIOUS DISEASES. MAR 1995, vol. 171, no. 3, March 1995 (1995-03), pages 645-651, XP009062267 ISSN: 0022-1899 * |
TANNICH E ET AL: "Primary structure of the 170-kDa surface lectin of pathogenic Entamoeba histolytica." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 1 MAR 1991, vol. 88, no. 5, 1 March 1991 (1991-03-01), pages 1849-1853, XP002369815 ISSN: 0027-8424 cited in the application * |
Also Published As
Publication number | Publication date |
---|---|
CN101052412A (en) | 2007-10-10 |
WO2006009862A3 (en) | 2006-06-15 |
CN101052412B (en) | 2010-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8367070B2 (en) | Modified surface antigen | |
Pruksakorn et al. | Conserved T and B cell epitopes on the M protein of group A streptococci. Induction of bactericidal antibodies. | |
US20070087012A1 (en) | Novel therapeutic target for protozoal diseases | |
AU2006214694B2 (en) | A plasmodium vivax hybrid circumsporozoite protein and vaccine | |
EP0429816A1 (en) | Vaccine composition with non-immunosuppresive T-cell epitope component | |
JPS62224293A (en) | Antigenic protein for preventing coccidiosis and vaccine containing the same | |
EP0519547B1 (en) | Coccidiosis poultry vaccine | |
EP1141305B1 (en) | Chimeric gene encoding the antigenic determinants of four proteins of l. infantum | |
AU2009227821A1 (en) | GBS Toxin Receptor | |
US6187310B1 (en) | Recombinant Entamoeba histolytica lectin subunit peptides and reagents specific for members of the 170 kDa subunit multigene family | |
WO2006009862A2 (en) | Amebiasis subunit vaccine | |
Precigout et al. | Association between sequence polymorphism in an epitope of Babesia divergens Bd37 exoantigen and protection induced by passive transfer | |
Banic et al. | Immune response and lack of immune response to Plasmodium falciparum P126 antigen and its amino-terminal repeat in malaria-infected humans. | |
US6710166B1 (en) | 41 kDa Cryptosporidium parvum oocyst wall protein | |
AU777145B2 (en) | Antigenic protein LPPQ of Mycoplasma mycoidessubsp.(mycoides)SC., its preparation and use | |
ES2334706T3 (en) | VACCINES AGAINST MALARIA. | |
SURI et al. | Evaluation of recombinant protein r140, a polypeptide segment of tegumental glycoprotein Sm25, as a defined antigen vaccine against Schistosoma mansoni | |
Salvatore et al. | Identification of antigenically active tryptic fragments of apical membrane antigen-1 (AMA1) of Plasmodium chabaudi malaria: strategies for assembly of immunologically active peptides | |
JPH10298104A (en) | Vaccine | |
EP1624063B1 (en) | Chimeric gene encoding the antigenic determinants of four proteins of L. infantum | |
US5670362A (en) | DNA encoding an Eimeria 100kD antigen | |
CA2253834A1 (en) | B. burgdorferi polypeptides expressed in vivo | |
AU7479894A (en) | Novel eimeria antibodies and antigens and methods of using the same | |
Ogun et al. | The oligomerization domain of C4-binding protein acts as an adjuvant: a fusion protein of MSP119 with the murine C4bp domain protects mice against malaria. | |
Bet-Dagan | S keS eeeeS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 215/KOLNP/2007 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580027998.3 Country of ref document: CN |
|
122 | Ep: pct application non-entry in european phase |